Vol 31, No 2 (2024)
Letter to the Editor
Published online: 2024-04-26

open access

Page views 182
Article views/downloads 118
Get Citation

Connect on Social Media

Connect on Social Media

Should dual antiplatelet treatment be guided by lipoprotein(a) concentration?

Jacek Kubica1
Pubmed: 38686990
Cardiol J 2024;31(2):363-364.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Lampsas S, Xenou M, Oikonomou E, et al. Lipoprotein(a) in atherosclerotic diseases: from pathophysiology to diagnosis and treatment. Molecules. 2023; 28(3).
  2. Cui K, Wu S, Yin D, et al. Prolonged dual antiplatelet therapy in invasively treated acute coronary syndrome patients with different lipoprotein(a) concentrations. Cardiol J. 2023 [Epub ahead of print].
  3. Navarese EP, Lansky AJ, Farkouh ME, et al. Effects of elective coronary revascularization vs medical therapy alone on noncardiac mortality: a meta-analysis. JACC Cardiovasc Interv. 2023; 16(10): 1144–1156.
  4. Kubica J, Adamski P, Gorog DA, et al. Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. Cardiol J. 2020; 27(6): 661–676.
  5. Kubica J, Adamski P, Niezgoda P, et al. A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study. Cardiol J. 2021; 28(4): 607–614.
  6. Navarese EP, Brouwer MA, Kubica J. Long-Term outcomes following coronary revascularizations in diabetes mellitus: the emerging role of LDL-C thresholds. J Am Coll Cardiol. 2020; 76(19): 2208–2211.
  7. Kubica J, Adamski P, Niezgoda P, et al. Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. Cardiol J. 2020; 27(6): 661–676.
  8. Kanji R, Kubica J, Navarese EP, et al. Endogenous fibrinolysis-Relevance to clinical thrombosis risk assessment. Eur J Clin Invest. 2021; 51(4): e13471.
  9. Adamski P, Ostrowska M, Navarese EP, et al. Pharmacodynamic and clinical efficacy of reduced ticagrelor maintenance doses in patients with coronary artery disease. Curr Med Res Opin. 2021; 37(2): 195–206.
  10. Ostrowska M, Kubica J, Adamski P, et al. Stratified approaches to antiplatelet therapies based on platelet reactivity testing. Front Cardiovasc Med. 2019; 6: 176.